MHMengbo Hu

Mengbo Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengbo Hu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Policy optimized MedGemma for multimodal prostate cancer care

    by Jimeng Hu, Quan Zhou, Bohan Zeng, Boke Liu, Fangdie Ye, Mengbo Hu, Haowen Jiang

  • Open Access

    NOX4 suppresses malignant progression in prostate adenocarcinoma and functions as a potential diagnostic biomarker

    by Jimeng Hu, Min Zhou, Xiaobo Wu, Mengbo Hu

    Background: Prostate adenocarcinoma (PRAD) is a highly prevalent malignant tumor in males and exhibits substantial heterogeneity. Identifying key associated genes is therefore critical for improving disease diagnosis and therapeutic strategies. Methods: In this study, we first analyzed gene expression profiles to identify differentially expressed genes (DEGs) between PRAD and normal tissues. Subsequently, a weighted gene co-expression network analysis (WGCNA) was performed to elucidate the functional roles and signaling pathways of key genes, supported by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) enrichment analyses. To prioritize robust diagnostic markers, three machine learning algorithms, least absolute shrinkage and selection operator (LASSO) regression, support vector machine with recursive feature elimination (SVM-RFE), and random forest, were integrated, and their intersection yielded six core genes: AOX1, APOBEC3C, C8orf88, GCNT4, NOX4, and PHYHIPL. Immune infiltration analysis via the CIBERSORT algorithm revealed that these core genes were significantly correlated with multiple immune cell populations. Notably, NOX4 was highly expressed in PRAD tissues, and its expression was negatively correlated with M2 macrophages while positively correlated with neutrophils. To investigate the functional role of NOX4, we constructed both NOX4 knockdown and overexpression models in the DU145 and PC3 PRAD cell lines, respectively. Cell Counting Kit-8 (CCK-8) and wound healing assays demonstrated that both NOX4 knockdown and overexpression markedly inhibited the proliferation and migration of PRAD cells. Results: Results from the DCFH-DA fluorescence assay showed that NOX4 overexpression significantly elevated intracellular reactive oxygen species (ROS) levels and activated the PI3K/AKT/ERK signaling pathway in PRAD cells. Conclusions: These findings suggest that NOX4 may regulate the redox balance of PRAD cells while activating the PI3K/AKT signaling pathway.

  • Quantitative analysis and risk factors of high-grade encrustation in double-J stents after ureteroscopy and laser lithotripsy

    by Jimeng Hu, Wenshuo Zhao, Guilin Xiao, Fusu Gao, Minwei Peng, Renhui Huang, Kang Ouyang, Hai Qiu, Bin Zhong, Lu Wang, et al.

    To quantitatively evaluate high-grade encrustation in double-J (DJ) stents and identify its risk factors in patients undergoing ureteroscopy and laser lithotripsy. This retrospective study analyzed 56 encrusted DJ stents from patients post-ureteroscopy and laser lithotripsy. Encrustation severity was classified using the FECal (Forgotten, Encrusted, Calcified) grading system. Clinical, laboratory, and stent characteristic data were collected. Composition and extent of encrustation were assessed via inductively coupled plasma mass spectrometry (ICP-MS) and scanning electron microscopy (SEM). Logistic regression analysis was performed to identify risk factors for high-grade encrustation. Among the 56 encrusted stents, FECal grades were: I (n = 23), II (n = 12), III (n = 18), IV (n = 1), and V (n = 2). High-grade encrustation (Grades III-V) was significantly associated with female gender (66.7% vs. 34.3%, p = 0.019), urological stone history (33.3% vs. 5.7%, p = 0.010), and indwelling time > 4 weeks (52.4% vs. 25.7%, p = 0.044). Multivariate analysis confirmed indwelling time > 4 weeks as an independent risk factor (OR = 3.9, p = 0.049). Calcium oxalate was the main component, with encrustation initiating on black-ring areas and near side holes and gradually extending to cross-sectional regions. The FECal grading system effectively reflects encrustation severity. Indwelling time > 4 weeks is a key predictor of high-grade encrustation. Side holes and the black marker ring are high-risk areas for mineral deposition. Developing stents with improved biocompatibility and anti-encrustation coatings could mitigate encrustation risks.


  • Open Access

    Ginsenoside Rh2 targets SIRT1-mediated deacetylation to modulate ERα/AR balance and overcome endocrine therapy resistance in prostate cancer using 3D organoid models

    by Xinan Chen, Wei Luo, Yueying Ren, Zezhong Mou, Chenyang Xu, Jimeng Hu, Mengbo Hu, Haowen Jiang

    Resistance to endocrine therapy remains a major challenge in treating prostate cancer (PCa), highlighting the need for alternative therapeutic approaches. In this study, we investigated the potential of Ginsenoside Rh2 to counteract such resistance by influencing the SIRT1-dependent deacetylation pathway, thereby modulating the equilibrium between estrogen receptor α (ERα) and androgen receptor (AR). We proposed that Rh2 may suppress therapy-resistant PCa progression by adjusting ERα/AR transcriptional dynamics. Through network pharmacology analysis, key anti-PCa targets of Rh2 were identified, with Cytoscape enrichment indicating a pivotal role in AR signaling modulation. Functional validation was performed using 3D tumor organoids and human PCa cell lines (C4-2B and LNCaP) treated with Rh2 to assess cellular behaviors and receptor deacetylation status. Additionally, xenograft mouse models were employed to evaluate Rh2’s in vivo effects, based on tumor burden, serum PSA levels, and tissue histopathology. Rh2 treatment led to significant, dose- and time-dependent inhibition of PCa cell proliferation and metastatic traits, accompanied by restored ERα/AR balance through activation of SIRT1. In animal studies, Rh2 notably reduced tumor size, decreased PSA expression, and improved systemic health indicators. Collectively, our results suggest that Rh2 re-sensitizes PCa to endocrine therapy by targeting the SIRT1 pathway, positioning it as a promising phytochemical candidate for managing resistant PCa. This work provides mechanistic insights supporting Rh2’s potential for clinical translation. Graphical Abstract Rh2 effectively reversed endocrine resistance in prostate cancer through SIRT1 activation. Orthotopic xenograft models were established using BALB/c nude mice with LNCaP cells. PSA and tumor growth were assessed following Rh2 treatment. SIRT1-mediated deacetylation regulated ERα and AR expression.


  • Toward morphologically relevant extracellular matrix: nanofiber-hydrogel composites for tumor cell culture

    by Xingxing Liu, Yueying Ren, Sijia Fu, Xinan Chen, Mengbo Hu, Fujun Wang, Lu Wang, Chaojing Li

    The natural extracellular matrix (ECM) consists of a continuous integrated fibrin network and a negatively charged proteoglycan-based matrix.


  • Open Access

    Overexpression of Ubiquitin-Conjugating Enzyme E2C Is Associated with Worsened Prognosis in Prostate Cancer

    by Xiaobo Wu, Xingbo Long, Chenkai Ma, Yin Celeste Cheuk, Mengbo Hu, Jimeng Hu, Haowen Jiang

    To evaluate the role of ubiquitin-conjugating enzyme E2C (UBE2C) in prostate cancer (PCa) progression and prognosis, the TCGA and our PCa tissue microarray cohort were included in the study. Weighted gene co-expression network analysis (WGCNA) and non-negative matrix factorization were used to cluster patients and to screen genes that play a vital role in PCa progression (hub gene). Immunohistochemistry staining was used to evaluate the protein level of UBE2C in prostatic tissues. Through WGCNA, we found a gene co-expression module (named the purple module) that is strongly associated with the Gleason score, pathologic T stage, and biochemical recurrent status. Genes in the purple module are enriched in cell cycle and P53 signaling and help us to cluster patients into two groups with distinctive biochemical recurrent survival rates and TP53 mutation statuses. Further analysis showed UBE2C served as a hub gene in the purple module. The expression of UBE2C in PCa was significantly higher than that in paracancerous tissues and was remarkably associated with pathologic grade, Gleason score, and prognosis in PCa patients. To conclude, UBE2C is a PCa-progress-related gene and a biomarker for PCa patients. Therapy targeting UBE2C may serve as a promising treatment of PCa in the future.


  • Open Access

    Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis

    by Pei-De Bai, Meng-Bo Hu, Hua Xu, Wen-Hui Zhu, Ji-Meng Hu, Tian Yang, Hao-Wen Jiang, Qiang Ding

    The aim of the study is to investigate whether body mass index (BMI) affected pathological characteristics and biochemical recurrence (BCR) of prostate cancer after radical prostatectomy in Chinese men. Medical records of 211 Chinese patients who underwent radical prostatectomy between 2006 and 2014 were retrospectively reviewed, with follow-up time of 24.5 ± 27.0 months. Multivariate logistic and Cox regression analyses were applied to address the impact of BMI on adverse pathological outcomes and BCR following prostatectomy. A meta-analysis of published studies from MEDLINE or EMBASE was conducted to determine the relationship between BMI and BCR following prostatectomy among Asian populations. Higher BMI was positively correlated with higher biopsy Gleason score (odds ratios (OR) 1.163, 95 % confidence interval (CI) 1.023–1.322, P = 0.021) and pathological Gleason score (OR 1.220, 95 % CI 1.056–1.410, P = 0.007) in multivariate analysis. BCR was detected in 48 patients (22.7 %). Multivariate Cox proportional hazards analysis revealed that higher BMI (hazard ratio (HR) 1.145, 95 % CI 1.029–1.273, P = 0.013) and prostate-specific antigen (HR 1.659, 95 % CI 1.102–2.497, P = 0.015) levels were independent predictors of BCR. The meta-analysis enrolled eight Asian studies of 4145 patients treated by radical prostatectomy. Based on random-effects approach, a 5 kg/m2 increase in BMI was correlated with 28 % higher risk of BCR (HR 1.22, 95 % CI 0.86–1.72) without statistical significance. The present study suggested that higher BMI was an independent risk factor for a higher Gleason score, as well as an independent predictor of BCR after radical prostatectomy in Chinese patients. Meta-analysis of Asian studies also indicated that obese patients, although without statistical significance, might be more likely to suffer from BCR.


  • Open Access

    Higher Body Mass Index Increases the Risk for Biopsy-Mediated Detection of Prostate Cancer in Chinese Men

    by Meng-Bo Hu, Pei-De Bai, Yi-Shuo Wu, Li-Min Zhang, Hua Xu, Rong Na, Hao-Wen Jiang, Qiang Ding

    To investigate the relationship between body mass index (BMI) and prostate cancer (PCa) risk at biopsy in Chinese men. We retrospectively reviewed the records of 1,807 consecutive men who underwent initial multicore (≥10) prostate biopsy under transrectal ultrasound guidance between Dec 2004 and Feb 2014. BMI was categorised based on the Asian classification of obesity as follows: <18.5 (underweight), 18.5–22.9 (normal weight), 23–24.9 (overweight), 25–29.9 (moderately obese), and ≥30 kg/m2 (severely obese). The odds ratios (OR) of each BMI category for risk of PCa and high-grade prostate cancer (HGPCa, Gleason score ≥4+3) detection were estimated in crude, age-adjusted and multivariate-adjusted models. Prevalence ratios and accuracies of PSA predicted PCa were also estimated across BMI groups. In total, PCa was detected by biopsy in 750 (45.4%) men, and HGPCa was detected in 419 (25.4%) men. Compared with men of normal weight, underweight men and obese men were older and had higher prostate specific antigen levels. The risk of overall PCa detection via biopsy presented an obvious U-shaped relationship with BMI in crude analysis. Overall, 50.0%, 37.4%, 45.6% 54.4% and 74.1% of the men in the underweight, normal weight, overweight, moderately obese and severely obese groups, respectively, were diagnosed with PCa via biopsy. In multivariate analysis, obesity was significantly correlated with a higher risk of PCa detection (OR = 1.17, 95%CI 1.10–1.25, P<0.001). However, higher BMI was not correlated with HGPCa detection (OR = 1.03, 95%CI 0.97–1.09, P = 0.29). There were no significant differences in the accuracy of using PSA to predict PCa or HGPCa detection across different BMI categories. Obesity was associated with higher risk of PCa detection in the present Chinese biopsy population. No significant association was detected between obesity and HGPCa.